Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
ABT-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate Alzheimer disease patients receiving stable doses of acetylcholinesterase inhibitors. This phase 2 double-blind, placebo-controlled, proof-of-concept, and dose-finding study adaptively randomized patients to receive ABT-089 (5, 10, 15, 20, 30, or 35 mg once daily) or placebo for 12 weeks. The primary efficacy endpoint was the Alzheimer's Disease Assessment Scale, cognition subscale (ADAS-Cog) total score. A Bayesian response-adaptive randomization algorithm dynamically assigned allocation probabilities based on interim ADAS-Cog total scores. A normal dynamic linear model for dose-response relationships and a longitudinal model for predicting final ADAS-cog score were employed in the algorithm. Stopping criteria for futility or success were defined. The futility stopping criterion was met, terminating the study with 337 patients randomized. No dose-response relationship was observed and no dose demonstrated statistically significant improvement over placebo on ADAS-Cog or any secondary endpoint. ABT-089 was well tolerated at all dose levels. When administered as adjunctive therapy to acetylcholinesterase inhibitors, ABT-089 was not efficacious in mild to moderate Alzheimer disease. The adaptive study design enabled the examination of a broad dose range, enabled rapid determination of futility, and reduced patient exposure to nonefficacious doses of the investigational compound.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Levin, E. D., McClernon, F. J., & Rezvani, A. H. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0164-7 · Cited by 820
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Grottick, A. J., & Higgins, G. A. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00305-3 · Cited by 240
Wilens, T. E., & Decker, M. W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.002 · Cited by 164
Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. (1999) · Psychopharmacology · doi:10.1007/s002130050897 · Cited by 163
Cited by
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Prediction of Conversion to Alzheimer’s Disease with Longitudinal Measures and Time-To-Event Data
Li, K., Chan, W., Doody, R. S., Quinn, J., Luo, S., & Initiative, T. A. D. N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161201 · Cited by 126
Old and new acetylcholinesterase inhibitors for Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1216972 · Cited by 117
“Results showed that ABT-089 was well tolerated at all dose levels, but when administered as adjunctive therapy to AChEIs, it was not efficacious in mild to moderate AD [14].”
BackgroundSherva, R., Gross, A., Mukherjee, S., Koesterer, R., Amouyel, P., Bellenguez, C., Dufouil, C., Bennett, D. A., Chibnik, L., Cruchaga, C., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12106 · Cited by 54
Metadata
- Authors
- Lenz, R. A., Pritchett, Y. L., Berry, S. M., Llano, D. A., Han, S., Berry, D. A., Sadowsky, C. H., Abi-Saab, W. M., & Saltarelli, M. D.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2015-07
- Volume
- 29
- Issue
- 3
- Pages
- 192-199
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W2395181219
- Cited by
- 28
- References
- 13
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease. https://app.cochat.ai/papers/10.1097/wad.0000000000000093
- The paper
- Lenz, R. A., Pritchett, Y. L., Berry, S. M., Llano, D. A., Han, S., Berry, D. A., Sadowsky, C. H., Abi-Saab, W. M., & Saltarelli, M. D. (2015). Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/wad.0000000000000093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.